Bausch + Lomb Corporation (NYSE/TSX: BLCO) said its Phase 2 study of BL1107, an eye drop candidate for glaucoma, did ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE